The burden of severe depression: A review of diagnostic challenges and treatment alternatives

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

Among the factors making recognition of severe depression problematic for clinicians are the heterogeneous nature of the condition, lack of standardized definitions, and concomitant comorbidities that confound differential diagnosis of symptoms. The spectrum of severity in depressive disorders is extraordinarily broad, and severity assessment is comprised of several metrics including symptom intensity, diagnostic subtypes, suicidality risk, and hospitalization status. The overall diagnosis is achieved through consideration of symptom types and severities together with the degree of functional impairment as assessed by the psychiatric interview. It is likely that no single fundamental neurobiological defect underlies severe depression. The chronicity and heterogeneity of this disorder lead to frequent clinic visits and a longer course of treatment; therefore, successful approaches may require an arsenal of treatments with numerous mechanisms of action. The categories of drugs used to treat severe depression are detailed herein, as are several non-pharmacologic options including a number of experimental treatments. Pharmacotherapies include tricyclic antidepressants, selective serotonin reuptake inhibitors, atypical antidepressants such as serotonin-norepinephrine reuptake inhibitors and monoamine oxidase inhibitors, and combination and augmentation therapies. Drugs within each class are not equivalent, and efficacy may vary with symptom severity. Patient adherence makes tolerability another critical consideration in antidepressant choice. The role of non-pharmacological treatments such as electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation, and deep brain stimulation remain active avenues of investigation. Improved knowledge and treatment approaches for severe depression are necessary to facilitate remission, the ideal treatment goal.

Original languageEnglish
Pages (from-to)189-206
Number of pages18
JournalJournal of Psychiatric Research
Volume41
Issue number3-4
DOIs
StatePublished - Apr 1 2007
Externally publishedYes

Fingerprint

Depression
Therapeutics
Second-Generation Antidepressive Agents
Vagus Nerve Stimulation
Electroconvulsive Therapy
Deep Brain Stimulation
Monoamine Oxidase Inhibitors
Transcranial Magnetic Stimulation
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Patient Compliance
Depressive Disorder
Ambulatory Care
Pharmaceutical Preparations
Antidepressive Agents
Psychiatry
Comorbidity
Hospitalization
Differential Diagnosis
Interviews

Keywords

  • Electroconvulsive therapy
  • Selective serotonin reuptake inhibitor
  • Serotonin norepinephrine reuptake inhibitor
  • Severe depression
  • Transcranial magnetic stimulation
  • Tricyclic antidepressant
  • Vagus nerve stimulation

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

The burden of severe depression : A review of diagnostic challenges and treatment alternatives. / Nemeroff, Charles.

In: Journal of Psychiatric Research, Vol. 41, No. 3-4, 01.04.2007, p. 189-206.

Research output: Contribution to journalArticle

@article{3f068428e2a94a9095dc5c233c35cd70,
title = "The burden of severe depression: A review of diagnostic challenges and treatment alternatives",
abstract = "Among the factors making recognition of severe depression problematic for clinicians are the heterogeneous nature of the condition, lack of standardized definitions, and concomitant comorbidities that confound differential diagnosis of symptoms. The spectrum of severity in depressive disorders is extraordinarily broad, and severity assessment is comprised of several metrics including symptom intensity, diagnostic subtypes, suicidality risk, and hospitalization status. The overall diagnosis is achieved through consideration of symptom types and severities together with the degree of functional impairment as assessed by the psychiatric interview. It is likely that no single fundamental neurobiological defect underlies severe depression. The chronicity and heterogeneity of this disorder lead to frequent clinic visits and a longer course of treatment; therefore, successful approaches may require an arsenal of treatments with numerous mechanisms of action. The categories of drugs used to treat severe depression are detailed herein, as are several non-pharmacologic options including a number of experimental treatments. Pharmacotherapies include tricyclic antidepressants, selective serotonin reuptake inhibitors, atypical antidepressants such as serotonin-norepinephrine reuptake inhibitors and monoamine oxidase inhibitors, and combination and augmentation therapies. Drugs within each class are not equivalent, and efficacy may vary with symptom severity. Patient adherence makes tolerability another critical consideration in antidepressant choice. The role of non-pharmacological treatments such as electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation, and deep brain stimulation remain active avenues of investigation. Improved knowledge and treatment approaches for severe depression are necessary to facilitate remission, the ideal treatment goal.",
keywords = "Electroconvulsive therapy, Selective serotonin reuptake inhibitor, Serotonin norepinephrine reuptake inhibitor, Severe depression, Transcranial magnetic stimulation, Tricyclic antidepressant, Vagus nerve stimulation",
author = "Charles Nemeroff",
year = "2007",
month = "4",
day = "1",
doi = "10.1016/j.jpsychires.2006.05.008",
language = "English",
volume = "41",
pages = "189--206",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "3-4",

}

TY - JOUR

T1 - The burden of severe depression

T2 - A review of diagnostic challenges and treatment alternatives

AU - Nemeroff, Charles

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Among the factors making recognition of severe depression problematic for clinicians are the heterogeneous nature of the condition, lack of standardized definitions, and concomitant comorbidities that confound differential diagnosis of symptoms. The spectrum of severity in depressive disorders is extraordinarily broad, and severity assessment is comprised of several metrics including symptom intensity, diagnostic subtypes, suicidality risk, and hospitalization status. The overall diagnosis is achieved through consideration of symptom types and severities together with the degree of functional impairment as assessed by the psychiatric interview. It is likely that no single fundamental neurobiological defect underlies severe depression. The chronicity and heterogeneity of this disorder lead to frequent clinic visits and a longer course of treatment; therefore, successful approaches may require an arsenal of treatments with numerous mechanisms of action. The categories of drugs used to treat severe depression are detailed herein, as are several non-pharmacologic options including a number of experimental treatments. Pharmacotherapies include tricyclic antidepressants, selective serotonin reuptake inhibitors, atypical antidepressants such as serotonin-norepinephrine reuptake inhibitors and monoamine oxidase inhibitors, and combination and augmentation therapies. Drugs within each class are not equivalent, and efficacy may vary with symptom severity. Patient adherence makes tolerability another critical consideration in antidepressant choice. The role of non-pharmacological treatments such as electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation, and deep brain stimulation remain active avenues of investigation. Improved knowledge and treatment approaches for severe depression are necessary to facilitate remission, the ideal treatment goal.

AB - Among the factors making recognition of severe depression problematic for clinicians are the heterogeneous nature of the condition, lack of standardized definitions, and concomitant comorbidities that confound differential diagnosis of symptoms. The spectrum of severity in depressive disorders is extraordinarily broad, and severity assessment is comprised of several metrics including symptom intensity, diagnostic subtypes, suicidality risk, and hospitalization status. The overall diagnosis is achieved through consideration of symptom types and severities together with the degree of functional impairment as assessed by the psychiatric interview. It is likely that no single fundamental neurobiological defect underlies severe depression. The chronicity and heterogeneity of this disorder lead to frequent clinic visits and a longer course of treatment; therefore, successful approaches may require an arsenal of treatments with numerous mechanisms of action. The categories of drugs used to treat severe depression are detailed herein, as are several non-pharmacologic options including a number of experimental treatments. Pharmacotherapies include tricyclic antidepressants, selective serotonin reuptake inhibitors, atypical antidepressants such as serotonin-norepinephrine reuptake inhibitors and monoamine oxidase inhibitors, and combination and augmentation therapies. Drugs within each class are not equivalent, and efficacy may vary with symptom severity. Patient adherence makes tolerability another critical consideration in antidepressant choice. The role of non-pharmacological treatments such as electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation, and deep brain stimulation remain active avenues of investigation. Improved knowledge and treatment approaches for severe depression are necessary to facilitate remission, the ideal treatment goal.

KW - Electroconvulsive therapy

KW - Selective serotonin reuptake inhibitor

KW - Serotonin norepinephrine reuptake inhibitor

KW - Severe depression

KW - Transcranial magnetic stimulation

KW - Tricyclic antidepressant

KW - Vagus nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=33845220058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845220058&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2006.05.008

DO - 10.1016/j.jpsychires.2006.05.008

M3 - Article

C2 - 16870212

AN - SCOPUS:33845220058

VL - 41

SP - 189

EP - 206

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 3-4

ER -